Juvaris BioTherapeutics was created in 2002 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancer using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create JuvImmuneTM, a single lipid-DNA complex, which as an immunostimulation product will have utility in a number of non-antigen immunotherapeutic applications. The DNA in these complexes does not code for protein, but rather, through a combined synergistic effect with lipids, strongly stimulates immune responses. The JuvImmuneTM product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants. Juvaris was recently issued Patent No. 6,693,086 titled Systemic Immune Activation Method Using Nucleic Acid-Lipid Complexes providing broad intellectual property coverage for the JuvImmuneTM technology.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/02/07 | Series A | 13.88M | Scholastic Corporation | Unknown |
People
Kimberlee Gonzaga (CFO)
Maggie Sisti (Director of Clinical Operations)
Lee Bussey (SVP Manufacturing)
Jeff Fairman (VP Research)
Grant Pickering (CEO)
View more details about all 11 people at Juvaris BioTherapeutics